2023 was a tough 12 months for the biopharma marketplace, with a number of firms downsizing and restructuring their workforces to remain afloat. You'll find signs of recovery, as mergers and acquisitions picked up over the pharmaceutical and lifetime sciences field within the latter Portion of 2023 and also have https://sites.google.com/view/bio-sites/blog